Real-world analysis of the impact of pemetrexed in firstline maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic
Fabio, Gomes Niall, G. Vivian, T. Katerina, C. Joanne, R. Amine, A. Adam, J. Anna, M.
Fabio, Gomes
Niall, G.
Vivian, T.
Katerina, C.
Joanne, R.
Amine, A.
Adam, J.
Anna, M.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Article
Citation
Fabio G, Niall G, Vivian T, Katerina C, Joanne R, Amine A, et al. Real-world analysis of the impact of pemetrexed in firstline maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic. Lung cancer (Amsterdam, Netherlands). 2024 APR;190:52-. PubMed PMID: WOS:001231921600001. English.